<code id='6F6375DB4F'></code><style id='6F6375DB4F'></style>
    • <acronym id='6F6375DB4F'></acronym>
      <center id='6F6375DB4F'><center id='6F6375DB4F'><tfoot id='6F6375DB4F'></tfoot></center><abbr id='6F6375DB4F'><dir id='6F6375DB4F'><tfoot id='6F6375DB4F'></tfoot><noframes id='6F6375DB4F'>

    • <optgroup id='6F6375DB4F'><strike id='6F6375DB4F'><sup id='6F6375DB4F'></sup></strike><code id='6F6375DB4F'></code></optgroup>
        1. <b id='6F6375DB4F'><label id='6F6375DB4F'><select id='6F6375DB4F'><dt id='6F6375DB4F'><span id='6F6375DB4F'></span></dt></select></label></b><u id='6F6375DB4F'></u>
          <i id='6F6375DB4F'><strike id='6F6375DB4F'><tt id='6F6375DB4F'><pre id='6F6375DB4F'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive